**Antibody response after a booster dose of SARS-CoV-2 vaccine in liver transplant recipients and those with chronic liver diseases.**

Mahak Chauhan, M.D., Ihechiluru Nzeako, M.D., Feng Li, PhD., Paul J. Thuluvath, MD.

**TABLE OF CONTENTS**

1. Supplementary Table 1. Response to booster dose stratified by the initial vaccine and the booster dose.
2. Supplementary Table 2: Patient characteristics of those who had poor antibody responses after the booster dose.

Supplementary Table 1. Response to booster dose stratified by the initial vaccine and the booster dose.

|  |  |
| --- | --- |
| Initial Vaccine (n) and Antibody titers (U/mL) | Booster Dose and Antibody Titers After (U/mL) |
| Pfizer | Moderna | JnJ |
| <0.8 | 0.8-249.9 | >250 | <0.8 | 0.8-249.9 | >250 | <0.8 | 0.8-249.9 | >250 |
| Pfizer (n=41)<0.80 (n =12)0.80-249.9 (n= 29) | 2 | 4 | 25 | 2 | 0 | 7 | 0 | 0 | 1 |
| Moderna (n=24)<0.80 (n=11)0.8-249.9 (n = 13) | 1 | 3 | 2 | 1 | 3 | 10 | 0 | 3 | 1 |
| JnJ (n=15)<0.80 (n= 3)0.80-249.9 (n= 12) | 0 | 1 | 9 | 1 | 1 | 2 | 0 | 0 | 1 |

**Supplementary Table 2: Patient characteristics of those who had poor antibody responses after the booster dose.**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Patient** | **Initial Vaccine** | **Initial Antibody Titer****U/mL** | **Booster Vaccine dose** | **Antibody Titer after Booster vaccine****U/mL** | **Days between initial vaccine and booster** | **Age** | **Sex** | **Race** | **BMI** | **Transplant** | **Cirrhosis** | **Etiology** | **Comorbidities** | **Medications** |
|  | Moderna | 0.4 | Pfizer | 1.4 | 124 | 44 | F | AA | 31 | Y | N | PSC | - | Tacrolimus, mycophenolate, prednisone |
|  | Moderna | 0.4 | Pfizer | 0.7 | 104 | 61 | M | AA | 35 | Y | N | NASH | CKD, COPD, DM, HTN | Tacrolimus, Prednisone |
|  | Moderna | 0.4 | JnJ | 16.2 | 65 | 65 | M | C | 28 | Y | N | Alcohol, HCC, HCV | COPD, HTN | Tacrolimus, mycophenolate |
|  | Pfizer | 0.4 | Pfizer | 6.5 | 81 | 69 | F | C | 32 | Y | N | HCC, HCV | CKD | Tacrolimus,prednisone |
|  | JnJ | 0.4 | Pfizer | 153.5 | 122 | 63 | F | C | 32 | Y | N | NASH | CKD, DM, HLD, HTN | Tacrolimus, mycophenolate |
|  | Pfizer | 0.4 | Moderna | 0.4 | 91 | 64 | F | C | 24 | Y | N | PBC | HLD, HTN | Tacrolimus, mycophenolate |
|  | JnJ | 0.4 | Moderna | 1.8 | 102 | 59 | M | C | 26 | N | Y/DC | Alcohol | - | - |
|  | Pfizer | 0.4 | Pfizer | 13 | 212 | 83 | F | C | 24 | N | Y/DC | NASH | - | - |
|  | Moderna | 0.4 | JnJ | 71.8 | 32 | 73 | F | C | 23 | N | N | AIH | HLD, HTN | Mycophenolate,prednisone |
|  | Pfizer | 0.4 | Pfizer | 0.4 | 116 | 64 | F | C | 24 | N | N | AIH | HLD, HTN | Mycophenolate,prednisone |
|  | Pfizer | 0.4 | Moderna | 0.4 | 103 | 53 | M | C | 31 | N | N | AIH | HLD, HTN | Mycophenolate,prednisone |
|  | Moderna | 0.4 | Pfizer | 17.7 | 125 | 63 | F | C | 21 | N | N | NAFLD | HLD, HTN | - |
|  | Pfizer | 0.4 | Pfizer | 0.4 | 59 | 70 | M | AA | 26 | Y | N | HCV | HTN | Tacrolimus |
|  | Moderna | 0.5 | Moderna | 29 | 47 | 65 | M | C | 42 | Y | N | Alcohol, HCC | CKD, HTN | Tacrolimus |
|  | Moderna | 0.5 | JnJ | 1.4 | 57 | 73 | M | C | 35 | Y | N | Alcohol | HLD | Tacrolimus, mycophenolate, prednisone |
|  | JnJ | 1.0 | Moderna | 0.4 | 90 | 61 | F | C | 22 | Y | N | Alcohol | - | Tacrolimus, Mycophenolate |
|  | Moderna | 1.4 | Pfizer | 46 | 35 | 57 | M | C | 29 | Y | N | PSC | CKD, DM | Tacrolimus |
|  | Pfizer | 4.4 | Pfizer | 93.3 | 88 | 65 | F | AA | 27 | Y | N | HCC, HCV | CAD, CKD, DM, HLD, HTN | Mycophenolate,prednisone |
|  | Moderna | 15.6 | Moderna | 38.8 | 119 | 69 | F | C | 28 | Y | N | NASH | CKD, DM, HLD, HTN | Tacrolimus |
|  | Pfizer | 106 | Pfizer | 87.7 | 179 | 84 | F | C | 29 | N | N | HCV | COPD, HTN | - |
|  | Moderna | 183.2 | Moderna | 0.4 | 163 | 80 | M | AA | 29 | N | Y/CC | HCC, HCV | CAD, DM, HLD, HTN | - |
|  | Moderna | 226.1 | Moderna | 112.9 | 101 | 52 | M | C | 23 | Y | N | Alcohol | COPD, DM | - |

AA: African American; AIH: autoimmune hepatitis; C: Caucasian; CC: compensated cirrhosis; CAD: coronary artery disease; CKD: chronic kidney disease; COPD: chronic obstructive pulmonary disease; DC: decompensated cirrhosis; DM: diabetes mellitus; HCV: hepatitis C virus; HLD: hyperlipidemia; HTN: hypertension; N: no; NAFLD: non-alcoholic fatty liver disease; NASH: non-alcoholic steatohepatitis; PSC: primary sclerosing cholangitis; PBC: primary biliary cholangitis; Y: yes